AZN vs ICCC · P/E 28, $288.38B cap vs rev $17.5M
AstraZeneca PLC (AZN) versus ImmuCell Corporation (ICCC) — a side-by-side from cached financials, not a winner call.
AstraZeneca PLC (AZN) is a drug manufacturers - general company listed on US.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
AZN does not have a complete income-statement cache yet.
Latest reported ICCC revenue for 2026-06-30 was $17.5M. Net income was $3.8M. Revenue was up 69.4% from 2026-03-31 to 2026-06-30. ICCC currently screens at market cap $58.9M.
AZN currently screens at market cap $288.38B and trailing P/E 28.0. ICCC currently screens at market cap $58.9M.
Not investment advice. Open the AZN and ICCC stock pages for the full models.
Not investment advice.